1. Home
  2. MGLD vs VERU Comparison

MGLD vs VERU Comparison

Compare MGLD & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Marygold Companies Inc.

MGLD

The Marygold Companies Inc.

HOLD

Current Price

$1.11

Market Cap

50.8M

Sector

Finance

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.28

Market Cap

48.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGLD
VERU
Founded
1996
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.8M
48.2M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
MGLD
VERU
Price
$1.11
$2.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
4.2K
283.3K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,876,734.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.36
52 Week High
$1.38
$7.33

Technical Indicators

Market Signals
Indicator
MGLD
VERU
Relative Strength Index (RSI) 46.01 40.84
Support Level $1.06 $2.11
Resistance Level $1.23 $2.74
Average True Range (ATR) 0.03 0.18
MACD -0.00 -0.04
Stochastic Oscillator 1.90 13.33

Price Performance

Historical Comparison
MGLD
VERU

About MGLD The Marygold Companies Inc.

The Marygold Companies Inc is an international holding company focused on acquiring and growing profitable businesses. Its main segments include U.S. Fund Management through USCF Investments, Food Products via Gourmet Foods and Printstock Products in New Zealand, Beauty Products under the Original Sprout brand, and formerly Security Systems through Brigadier, sold in 2025. The majority of revenue comes from fund management. The company operates in the USA, New Zealand, the United Kingdom, and Canada, with the majority of revenue generated from the USA. Its business approach focuses on strengthening financial services, expanding fintech, and managing a diverse portfolio for growth.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: